CARE-MS II

#CMSC2018 – Gains in Functional Abilities Seen in Lemtrada-treated MS Patients Over Six Years, CARE-MS II Extension Study Shows

Patients with active relapsing-remitting multiple sclerosis (MS) continue to show improvement ā€” lesser functional disability across a variety of measures ā€” and often without the need for continuous treatment after takingĀ LemtradaĀ for two years, according to six-year results from the CARE-MS II extension study. These results were shared in a…

Lemtrada Lessens MS Disability in People Who Respond Poorly to Other Therapies, Study Says

Data from the CARE-MS II clinical trialĀ showed that Lemtrada (alemtuzumab) canĀ lessen pre-existing disabilities in patients with relapsing-remitting multiple sclerosis (RRMS) who failed to respond adequately to previous disease-modifying therapies, according to a study of the trial’s data. The treatment was evaluated againstĀ Rebif (interferon beta-1a)Ā therapy. The study, ā€œAlemtuzumab…

Lemtrada to Treat Relapsing MS Now Part of New Brunswick, Canada, Drug Program

The Government ofĀ New Brunswick added Ā Lemtrada (alemtuzumab), byĀ Sanofi Genzyme,Ā to the New Brunswick Prescription Drug Program (NBPDP) through special authorization for eligibleĀ patients with relapsing-remitting multiple sclerosis (RRMS). New BrunswickĀ joins other Canadian provinces, includingĀ Ontario, Saskatchewan,Ā Quebec, and Manitoba, in making this treatment available to RRMS patients, ages 18 andĀ older,Ā who have had…